• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Experience with HSP90 inhibitor AUY922 in patients with relapsed or refractory non-Hodgkin lymphoma.

作者信息

Oki Yasuhiro, Younes Anas, Knickerbocker Javier, Samaniego Felipe, Nastoupil Loretta, Hagemeister Fredrick, Romaguera Jorge, Fowler Nathan, Kwak Larry, Westin Jason

机构信息

Department of Lymphoma and Myeloma, University of Texas, MD Anderson Cancer Center, Houston, TX 77030 USA

Department of Lymphoma and Myeloma, University of Texas, MD Anderson Cancer Center, Houston, TX 77030 USA.

出版信息

Haematologica. 2015 Jul;100(7):e272-4. doi: 10.3324/haematol.2015.126557. Epub 2015 Mar 27.

DOI:10.3324/haematol.2015.126557
PMID:25820332
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4486240/
Abstract
摘要

相似文献

1
Experience with HSP90 inhibitor AUY922 in patients with relapsed or refractory non-Hodgkin lymphoma.热休克蛋白90抑制剂AUY922用于复发或难治性非霍奇金淋巴瘤患者的经验。
Haematologica. 2015 Jul;100(7):e272-4. doi: 10.3324/haematol.2015.126557. Epub 2015 Mar 27.
2
A Phase 2 Study of the Hsp90 Inhibitor AUY922 as Treatment for Patients with Refractory Gastrointestinal Stromal Tumors.热休克蛋白90抑制剂AUY922治疗难治性胃肠道间质瘤患者的2期研究
Cancer Invest. 2016 Jul 2;34(6):265-70. doi: 10.1080/07357907.2016.1193746. Epub 2016 Jul 5.
3
AUY922 effectively targets against activated B cell subtype of diffuse large B-cell lymphoma and low-grade lymphoma cells harboring genetic alteration-associated nuclear factor-κB activation.AUY922可有效靶向弥漫性大B细胞淋巴瘤的活化B细胞亚型以及携带与核因子κB激活相关基因改变的低度淋巴瘤细胞。
Leuk Lymphoma. 2015;56(9):2674-82. doi: 10.3109/10428194.2014.995647. Epub 2015 Jan 21.
4
Phase 1/1B trial of the heat shock protein 90 inhibitor NVP-AUY922 as monotherapy or in combination with bortezomib in patients with relapsed or refractory multiple myeloma.NVP-AUY922（热休克蛋白 90 抑制剂）单药或联合硼替佐米治疗复发或难治性多发性骨髓瘤患者的 1/1B 期临床试验。
Cancer. 2015 Jul 1;121(13):2185-92. doi: 10.1002/cncr.29339. Epub 2015 Mar 24.
5
Targeting HSP90 with the small molecule inhibitor AUY922 (luminespib) as a treatment strategy against hepatocellular carcinoma.以小分子抑制剂 AUY922（luminespib）靶向 HSP90 作为治疗肝细胞癌的策略。
Int J Cancer. 2019 May 15;144(10):2613-2624. doi: 10.1002/ijc.31963. Epub 2018 Dec 24.
6
2-phenylethynesulphonamide (PFT-μ) enhances the anticancer effect of the novel hsp90 inhibitor NVP-AUY922 in melanoma, by reducing GSH levels.2-苯乙炔磺酰胺（PFT-μ）通过降低谷胱甘肽水平，增强了新型热休克蛋白90抑制剂NVP-AUY922对黑色素瘤的抗癌作用。
Pigment Cell Melanoma Res. 2016 May;29(3):352-71. doi: 10.1111/pcmr.12472.
7
NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis.NVP-AUY922：一种新型热休克蛋白90抑制剂，对异种移植肿瘤生长、血管生成和转移具有活性。
Cancer Res. 2008 Apr 15;68(8):2850-60. doi: 10.1158/0008-5472.CAN-07-5256.
8
A Phase I Study of the Hsp90 Inhibitor AUY922 plus Capecitabine for the Treatment of Patients with Advanced Solid Tumors.热休克蛋白90抑制剂AUY922联合卡培他滨治疗晚期实体瘤患者的I期研究
Cancer Invest. 2015;33(10):477-82. doi: 10.3109/07357907.2015.1069834. Epub 2015 Oct 13.
9
Brentuximab vedotin in refractory or relapsed peripheral T-cell lymphomas: the French named patient program experience in 56 patients.本妥昔单抗治疗难治性或复发性外周T细胞淋巴瘤：法国特定患者项目中56例患者的经验
Haematologica. 2016 Mar;101(3):e103-6. doi: 10.3324/haematol.2015.135400. Epub 2015 Dec 24.
10
Novel HSP90 inhibitor NVP-AUY922 enhances the anti-tumor effect of temsirolimus against oral squamous cell carcinoma.新型 HSP90 抑制剂 NVP-AUY922 增强了替西罗莫司对口腔鳞状细胞癌的抗肿瘤作用。
Curr Cancer Drug Targets. 2013 Mar;13(3):289-99. doi: 10.2174/1568009611313030007.

引用本文的文献

1
Ageing microenvironment mediates lymphocyte carcinogenesis and lymphoma drug resistance: From mechanisms to clinical therapy (Review).衰老微环境介导淋巴细胞癌发生和淋巴瘤耐药性：从机制到临床治疗（综述）。
Int J Oncol. 2024 Jun;64(6). doi: 10.3892/ijo.2024.5653. Epub 2024 May 17.
2
Cytokine-Induced Killer Cells in Combination with Heat Shock Protein 90 Inhibitors Functioning via the Fas/FasL Axis Provides Rationale for a Potential Clinical Benefit in Burkitt's lymphoma.细胞因子诱导的杀伤细胞与热休克蛋白 90 抑制剂联合作用通过 Fas/FasL 轴提供了在伯基特淋巴瘤中具有潜在临床获益的理由。
Int J Mol Sci. 2023 Aug 5;24(15):12476. doi: 10.3390/ijms241512476.
3
Elucidation of the Molecular Pathways Involved in the Protective Effects of AUY-922 in LPS-Induced Inflammation in Mouse Lungs.阐明AUY-922对小鼠肺部脂多糖诱导炎症的保护作用所涉及的分子途径。
Pharmaceuticals (Basel). 2021 May 29;14(6):522. doi: 10.3390/ph14060522.
4
Heat-activated nanomedicine formulation improves the anticancer potential of the HSP90 inhibitor luminespib in vitro.热激活纳米药物制剂提高 HSP90 抑制剂 luminespib 的体外抗癌潜力。
Sci Rep. 2021 May 27;11(1):11103. doi: 10.1038/s41598-021-90585-w.
5
Heat Shock Proteins in Lymphoma Immunotherapy.热休克蛋白在淋巴瘤免疫治疗中的作用。
Front Immunol. 2021 Mar 18;12:660085. doi: 10.3389/fimmu.2021.660085. eCollection 2021.
6
HSP90 Inhibition and Modulation of the Proteome: Therapeutical Implications for Idiopathic Pulmonary Fibrosis (IPF).热休克蛋白 90 抑制与蛋白质组调节：特发性肺纤维化（IPF）的治疗意义。
Int J Mol Sci. 2020 Jul 25;21(15):5286. doi: 10.3390/ijms21155286.
7
Block-And-Lock Strategies to Cure HIV Infection.阻断与锁定策略治愈 HIV 感染。
Viruses. 2020 Jan 10;12(1):84. doi: 10.3390/v12010084.
8
Hsp90 chaperones hemoglobin maturation in erythroid and nonerythroid cells.Hsp90 伴侣蛋白在红细胞和非红细胞中辅助血红蛋白成熟。
Proc Natl Acad Sci U S A. 2018 Feb 6;115(6):E1117-E1126. doi: 10.1073/pnas.1717993115. Epub 2018 Jan 22.

本文引用的文献

1
First-in-human phase I dose-escalation study of the HSP90 inhibitor AUY922 in patients with advanced solid tumors.人用 I 期剂量递增研究 HSP90 抑制剂 AUY922 在晚期实体瘤患者中的应用。
Clin Cancer Res. 2013 Jul 1;19(13):3671-80. doi: 10.1158/1078-0432.CCR-12-3404. Epub 2013 Jun 11.
2
The HSP90 inhibitor NVP-AUY922-AG inhibits the PI3K and IKK signalling pathways and synergizes with cytarabine in acute myeloid leukaemia cells.HSP90 抑制剂 NVP-AUY922-AG 抑制 PI3K 和 IKK 信号通路，并与阿糖胞苷在急性髓系白血病细胞中协同作用。
Br J Haematol. 2013 Apr;161(1):57-67. doi: 10.1111/bjh.12215. Epub 2013 Jan 29.
3
Heat shock protein-90 inhibitor, NVP-AUY922, is effective in combination with fludarabine against chronic lymphocytic leukemia cells cultured on CD40L-stromal layer and inhibits their activated/proliferative phenotype.热休克蛋白 90 抑制剂 NVP-AUY922 与氟达拉滨联合用于在 CD40L 基质层上培养的慢性淋巴细胞白血病细胞具有疗效，并抑制其激活/增殖表型。
Leuk Lymphoma. 2012 Nov;53(11):2314-20. doi: 10.3109/10428194.2012.698278. Epub 2012 Jul 9.
4
Clinical experience with the heat shock protein-90 inhibitor, tanespimycin, in patients with relapsed lymphoma.热休克蛋白90抑制剂坦西莫司治疗复发淋巴瘤患者的临床经验。
Leuk Lymphoma. 2012 May;53(5):990-2. doi: 10.3109/10428194.2011.631236. Epub 2012 Mar 13.
5
Targeting the dynamic HSP90 complex in cancer.针对癌症中的动态 HSP90 复合物。
Nat Rev Cancer. 2010 Aug;10(8):537-49. doi: 10.1038/nrc2887.
6
Synergistic action of the novel HSP90 inhibitor NVP-AUY922 with histone deacetylase inhibitors, melphalan, or doxorubicin in multiple myeloma.新型 HSP90 抑制剂 NVP-AUY922 与组蛋白去乙酰化酶抑制剂、美法仑或阿霉素联合应用于多发性骨髓瘤的协同作用。
Eur J Haematol. 2010 Apr;84(4):337-44. doi: 10.1111/j.1600-0609.2009.01403.x. Epub 2009 Dec 17.
7
HDAC6 inhibition enhances 17-AAG--mediated abrogation of hsp90 chaperone function in human leukemia cells.组蛋白去乙酰化酶6抑制增强17-烯二炔类抗生素介导的人白血病细胞中热休克蛋白90伴侣功能的消除。
Blood. 2008 Sep 1;112(5):1886-93. doi: 10.1182/blood-2008-03-143644. Epub 2008 Jun 30.
8
NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models.NVP-AUY922：一种在临床前乳腺癌模型中具有强大抗肿瘤活性的小分子热休克蛋白90抑制剂。
Breast Cancer Res. 2008;10(2):R33. doi: 10.1186/bcr1996. Epub 2008 Apr 22.
9
NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis.NVP-AUY922：一种新型热休克蛋白90抑制剂，对异种移植肿瘤生长、血管生成和转移具有活性。
Cancer Res. 2008 Apr 15;68(8):2850-60. doi: 10.1158/0008-5472.CAN-07-5256.
10
Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies.17-烯丙基氨基-17-去甲氧基格尔德霉素在晚期恶性肿瘤患者中的I期药代动力学和药效学研究。
J Clin Oncol. 2005 Jun 20;23(18):4152-61. doi: 10.1200/JCO.2005.00.612.